Legend Biotech

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Legend Biotech surpasses Q2 sales targets, eyes market expansion

Legend Biotech's Q2 performance exceeded expectations with strong sales and positive study data.
The company's financial position is robust, with a healthy cash balance and plans for capacity expansion.
While facing challenges such as competitive pressures and operational optimizations, opportunities for growth exist.
Strategic initiatives focus on product quality, market expansion, and regulatory advancements for CARVYKTI.

Legend Biotech reports robust Q3 sales, eyes profitability targets

Legend Biotech's Q3 performance reflects strong sales driven by CARVYKTI, while maintaining a solid financial position with a focus on expansion.
The company faces challenges in achieving profitability targets and providing clarity on future sales projections.
Opportunities lie in pipeline advancements, collaboration partnerships, and innovative market expansion strategies.

Legend Biotech reports robust earnings, eyes expansion and regulatory milestones

Legend Biotech's strong earnings and cash balance provide stability and growth opportunities.
CARVYKTI's efficacy and convenience position it well, with plans for capacity expansion and partnerships.
Challenges include regulatory scrutiny and the need for clarity on future manufacturing scale-up.
Opportunities lie in extending manufacturing capacity, pipeline advancements, and profitability projections by 2026.

Legend Biotech reports robust Q1 performance and accelerates CAR-T expansion

Legend Biotech's Q1 2024 showcased strong performance with significant revenue growth and expansion plans to meet rising demand.
While facing challenges like sequential sales decrease and increased expenses, the company is leveraging strengths in production capacity and market diversification.
Opportunities lie in regulatory engagements for accelerated approvals, efficient market penetration strategies, and financial flexibility for future growth.
Overall, Legend Biotech's strategic focus on CAR-T therapies positions it well for continued success and innovation in the biopharmaceutical industry.

Legend Biotech excels in Q2, eyes FDA approvals and growth

Legend Biotech's Q2 2024 performance reflects strong sales growth, regulatory milestones, and promising clinical data, positioning the company for future success.
With a solid financial position, expanded production capacity, and ongoing research initiatives, Legend Biotech demonstrates resilience and strategic foresight in a competitive market landscape.
While facing challenges such as political risks and profitability targets, the company remains focused on growth opportunities and value creation for stakeholders.

Legend Biotech excels in Q3 with CARVYKTI growth and strategic advancements

Legend Biotech's Q3 performance reflects strong sales growth, regulatory milestones, and progress in clinical trials, underpinned by a robust balance sheet and strategic leadership appointments.
While challenges in outpatient treatment adoption and trial enrollment persist, the company's focus on innovation and operational excellence presents opportunities for future growth and market leadership.
Overall, Legend Biotech's solid financial standing, coupled with its expanding product portfolio and research capabilities, positions the company favorably for continued success and value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

SOMERSET, N.J.--(BUSINESS WIRE)-- #LegendBiotech--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today the initiation of a rolling submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric an

Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

AbbVie

ADC Therapeutics

Allogene Therapeutics Inc

BioNTech SE

Y-Mabs Therapeutics Inc

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie.

Week In Review: Week's China Life Science Investments Total $800 Million

SOMERSET, N.J.--(BUSINESS WIRE)-- #JPM2021--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021. Ying Huang, PhD, Chief Executive Officer and Chief Financial Officer of Legend Biotech, will present company updates on Wednesday, January 13, 2

Legend Biotech to Participate in the 39th Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)-- #biotech--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 21, 2020. For this year's re-

Legend Biotech Added to the NASDAQ Biotechnology Index

SOMERSET, N.J.--(BUSINESS WIRE)-- #LYMSM--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to evaluate LB1901, the company's investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment

Legend Biotech Announces FDA Clearance of the IND for LB1901, an Investigational Autologous Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma

bluebird bio

Bristol-Myers

Johnson & Johnson

Regeneron Pharmaceuticals

Targeting BCMA is all the rage, but who will come out on top?

ASH Annual Meeting: Drugmakers Battle for Multiple Myeloma

Drugmakers are targeting B-cell maturation antigen in different ways.

Here's the Hot Target for Multiple Myeloma Drugs

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the latest data results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA) directed chimeric antigen receptor T cell (CAR-T) therapy,

Legend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that it has appointed Dr. Patrick Casey as an independent director to Legend Biotech's Board of Directors. Dr. Casey will serve as a Class II director. “We are delighted to have Dr. Casey join our Board of Directors,” said Sally Wang, Ch

Legend Biotech Announces Appointment of Dr. Patrick Casey to the Board of Directors

SOMERSET, N.J.--(BUSINESS WIRE)-- #ASH20--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, December 7 at 7 pm ET highlighting the latest data from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) of ciltacabtagene autoleucel (cilta-cel), an investigational BCMA-directed CAR-T cell therapy being studied for the treatment of patients with relapsed or refractory multiple myeloma. This will follow the oral presenta

Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual Meeting

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that it has appointed Dr. Li Zhu to Legend Biotech's Board of Directors. Dr. Zhu will serve as a Class III director. In addition, Dr. Fangliang Zhang tendered his resignation from the Board of Directors of Legend Biotech and its committe

Legend Biotech Announces New Appointment to the Board of Directors and Resignation of Dr. Fangliang Zhang

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported financial results for the quarter ended September 30, 2020. “Legend Biotech continues to execute on our corporate strategy, advancing the development of our lead product candidate, ciltacabtagene autoleucel (cilta-cel), i

Legend Biotech Reports Third Quarter 2020 Financial Results

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that Ms. Ye (Sally) Wang was appointed, effective November 6, 2020, as Chairwoman of the Board of Directors of Legend Biotech. The Board of Directors also named Dr. Ying Huang as Chief Executive Officer of Legend Biotech, effective Novem

Legend Biotech Announces Leadership Transition

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that new and updated data from CARTITUDE-1 and LEGEND-2 studies, respectively, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020. CARTITUDE-1 data for

Legend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA CAR-T Cell Therapy in Development for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Legend Bio To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 1, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Legend Biotech Corporation ("Legend Bio" or the "Company") (NASDAQ:LEGN).If you suffered losses exceeding $50,000 investing in Legend Bio stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/LEGN or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext....

LEGEND BIO INVESTOR ALERT

New York, New York--(Newsfile Corp. - October 22, 2020) - Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend" or "the Company") (NASDAQ: LEGN) concerning possible violations of federal securities laws. On September 21, 2020, Legend Biotech announced in a press release that its Chief Executive Officer, Dr. Fangliang Zhang, was under re

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Legend Biotech Corporation

New York, New York--(Newsfile Corp. - October 8, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Legend Biotech Corporation ("Legend Bio" or the "Company") (NASDAQ:LEGN).If you suffered losses exceeding $50,000 investing in Legend Bio stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/LEGN. There is no cost or obligation to you.

Legend Bio Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Legend Biotech Corporation To Contact The Firm

BENSALEM, Pa.--(BUSINESS WIRE)---- $LEGN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Legend Biotech Corporation (LEGN) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Legend Biotech Corporation (LEGN) on Behalf of Investors

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the Jefferies Virtual Cell Therapy Summit on Tuesday, October 6th. Ying Huang, interim-Chief Executive Officer and Chief Financial Officer, will represent the Company in a session scheduled at 11:20 a.m. (Eastern Time). This webcast wi

Legend Biotech to Participate in the Jefferies Virtual Cell Therapy Summit

New York, New York--(Newsfile Corp. - September 26, 2020) -  Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Legend Biotech Corporation (NASDAQ: LEGN) resulting from allegations that Legend may have issued materially misleading business information to the investing public.On September 21, 2020, Legend disclosed that the Customs Anti-Smuggling Department of China inspected Legend Biotech's location in Nanjing. According to Legend, the inspection...

ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Legend Biotech Corporation - LEGN

Los Angeles, California--(Newsfile Corp. - September 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or "the Company") (NASDAQ: LEGN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Legend issued a press release on September 21, 2020, disclosing that...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Legend Biotech Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Legend Biotech Corporation (NASDAQ: LEGN) resulting from allegations that Legend may have issued materially misleading business information to the investing public. On September 21, 2020, Legend disclosed that the Customs Anti-Smuggling Department of China inspected Legend Biotech’s location in Nanjing. According to Legend, the insp

ROSEN LAW FIRM, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Legend Biotech Corporation – LEGN

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #CLASSACTION--Glancy Prongay & Murray LLP Continues Investigation on Behalf of Legend Biotech Corporation Investors (LEGN)

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Legend Biotech Corporation Investors (LEGN)

Legend Biotech (LEGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Legend Biotech (LEGN) in Focus: Stock Moves 6.2% Higher

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Legend Biotech Corporation (“Legend” or the “Company”) (NASDAQ: LEGN) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 21, 2020, Legend disclosed that the Customs Anti-Smuggling Department of China inspected Legend Biotech’s location in Nanjing. According to Legend, the in

News for Legend Biotech Stock (LEGN)